Diabetes may be independent risk factor for hyperkalaemia.
作者信息
Jarman Paul R, Mather Hugh M
出版信息
BMJ. 2003 Oct 4;327(7418):812. doi: 10.1136/bmj.327.7418.812.
Abstract
摘要
相似文献
1
Diabetes may be independent risk factor for hyperkalaemia.糖尿病可能是高钾血症的独立危险因素。
BMJ. 2003 Oct 4;327(7418):812. doi: 10.1136/bmj.327.7418.812.
2
Spironolactone + ace inhibitor or sartan: risk of hyperkalaemia.螺内酯 + 血管紧张素转换酶抑制剂或沙坦类药物：高钾血症风险
Prescrire Int. 2004 Apr;13(70):58.
3
[Drug-related hyperkalemia resulted from spironolactone and angiotensin converting enzyme inhibitors therapy].螺内酯和血管紧张素转换酶抑制剂治疗导致的药物相关性高钾血症
Pol Merkur Lekarski. 1999 Aug;7(38):69-70.
4
Drug safety in patients with heart failure.
Arch Intern Med. 2005 Jan 10;165(1):118. doi: 10.1001/archinte.165.1.118-a.
5
Life-threatening hyperkalaemia caused by ACE inhibitor and diuretics.
Diabet Med. 1997 Sep;14(9):808. doi: 10.1002/(SICI)1096-9136(199709)14:9<808::AID-DIA464>3.0.CO;2-2.
6
Life-threatening hyperkalaemia caused by angiotensin-converting enzyme-inhibitor and diuretics.血管紧张素转换酶抑制剂和利尿剂引起的危及生命的高钾血症。
Diabet Med. 1997 Feb;14(2):169-70. doi: 10.1002/(SICI)1096-9136(199702)14:2<169::AID-DIA307>3.0.CO;2-5.
7
Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone.血管紧张素转换酶抑制剂与螺内酯联合治疗期间的危及生命的高钾血症。
Am J Med. 2001 Nov;111(7):587. doi: 10.1016/s0002-9343(01)00927-5.
8
Drug-induced hyperkalaemia is frequent.药物性高钾血症很常见。
Prescrire Int. 2007 Feb;16(87):16.
9
Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone.使用血管紧张素转换酶抑制剂和螺内酯的充血性心力衰竭患者的高钾血症
Nephrol Dial Transplant. 2003 Sep;18(9):1814-9. doi: 10.1093/ndt/gfg295.
10
Hyperkalaemia in the age of aldosterone antagonism.醛固酮拮抗剂时代的高钾血症。
QJM. 2012 Nov;105(11):1049-57. doi: 10.1093/qjmed/hcs106. Epub 2012 Jun 20.
引用本文的文献
1
Nephroprotective Mechanisms of SGLT2i: Beyond the Glucose-Lowering Effect.钠-葡萄糖协同转运蛋白2抑制剂的肾保护机制：超越降糖作用
Biomedicines. 2025 Aug 30;13(9):2123. doi: 10.3390/biomedicines13092123.
2
Expanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings.扩大钠-葡萄糖协同转运蛋白2抑制剂在2型糖尿病患者不同临床场景中的应用。
Cells. 2025 May 2;14(9):668. doi: 10.3390/cells14090668.
3
Patiromer use in patients with heart failure: lessons and clinical considerations from the DIAMOND trial.帕替罗姆在心力衰竭患者中的应用：来自钻石试验的经验教训及临床考量
Eur J Heart Fail. 2022 Oct;24(10):1744-1747. doi: 10.1002/ejhf.2684. Epub 2022 Sep 20.
4
The Off-Target Effects, Electrolyte and Mineral Disorders of SGLT2i.SGLT2i 的脱靶效应、电解质和矿物质紊乱。
Molecules. 2020 Jun 15;25(12):2757. doi: 10.3390/molecules25122757.
5
Mineral and Electrolyte Disorders With SGLT2i Therapy.SGLT2抑制剂治疗相关的矿物质和电解质紊乱
JBMR Plus. 2019 Nov 4;3(11):e10242. doi: 10.1002/jbm4.10242. eCollection 2019 Nov.
6
Mineralocorticoid receptor antagonists for heart failure: a real-life observational study.醛固酮受体拮抗剂治疗心力衰竭：一项真实世界观察性研究。
ESC Heart Fail. 2018 Jun;5(3):267-274. doi: 10.1002/ehf2.12244. Epub 2018 Feb 4.
7
Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease.在心力衰竭合并糖尿病或慢性肾脏病的患者中使用盐皮质激素受体拮抗剂。
J Am Heart Assoc. 2017 Dec 23;6(12):e006540. doi: 10.1161/JAHA.117.006540.
8
Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.钠-葡萄糖协同转运蛋白2抑制剂达格列净对2型糖尿病患者血钾水平的影响：一项汇总分析
Diabetes Ther. 2016 Mar;7(1):125-37. doi: 10.1007/s13300-015-0150-y. Epub 2016 Jan 12.
9
Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial).盐皮质激素受体拮抗剂在射血分数降低的心力衰竭合并糖尿病住院患者中的应用（来自EVEREST试验）
Am J Cardiol. 2014 Sep 1;114(5):743-50. doi: 10.1016/j.amjcard.2014.05.064. Epub 2014 Jun 24.
10
Aldosterone antagonists in monotherapy are protective against streptozotocin-induced diabetic nephropathy in rats.醛固酮拮抗剂单药治疗可预防链脲佐菌素诱导的大鼠糖尿病肾病。
PLoS One. 2012;7(6):e39938. doi: 10.1371/journal.pone.0039938. Epub 2012 Jun 28.
本文引用的文献
1
Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.螺内酯与血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂的相互作用：44例分析。
BMJ. 2003 Jul 19;327(7407):147-9. doi: 10.1136/bmj.327.7407.147.
2
Life-threatening hyperkalaemia caused by angiotensin-converting enzyme-inhibitor and diuretics.血管紧张素转换酶抑制剂和利尿剂引起的危及生命的高钾血症。
Diabet Med. 1997 Feb;14(2):169-70. doi: 10.1002/(SICI)1096-9136(199702)14:2<169::AID-DIA307>3.0.CO;2-5.
3
Hyperkalaemia in diabetes: prevalence and associations.
Postgrad Med J. 1995 Sep;71(839):551-2. doi: 10.1136/pgmj.71.839.551.
4
Hyperkalemia in the elderly.老年人高钾血症
Clin Chem. 1984 Aug;30(8):1409-12.
Zotero 插件